Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 8930 results

  1. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Awaiting development Reference number: GID-TA11276 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]

    Awaiting development Reference number: GID-TA10198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]

    Awaiting development Reference number: GID-TA11222 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]

    Awaiting development Reference number: GID-TA11335 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Gantenerumab for treating early Alzheimer's disease [TSID10668]

    Awaiting development Reference number: GID-TA11072 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015]

    Awaiting development Reference number: GID-TA11551 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]

    Awaiting development Reference number: GID-TA11059 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development